Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia
This randomized clinical trial assesses the safety and effectiveness of plozasiran, an investigational APOC3-targeted drug, in the reduction of serum triglyceride level in patients with severe hypertriglyceridemia.